儿童肿瘤协作组:急性淋巴细胞白血病诱导期门冬酰胺酶毒性报告
该研究基于儿童肿瘤协作组AALL0232和AALL0434两项试验中4925例1-30岁患者的诱导数据,分析年龄、BMI和体表面积与门冬酰胺酶相关毒性的关联及其对诱导末MRD的影响。结果显示≥10岁、肥胖伴高体表面积者毒性风险增加,但毒性未影响EOI MRD阳性率。
要点
- 肥胖伴高体表面积者高胆红素血症、ALT升高和血栓风险均增加。
- 门冬酰胺酶相关毒性与诱导末MRD阳性(≥0.01%)无关联。
核心结论
- 年龄≥10岁及肥胖伴高体表面积与门冬酰胺酶相关毒性风险增加有关,但毒性未影响诱导末MRD阳性率。
研究设计与样本
- 回顾性分析儿童肿瘤协作组AALL0232和AALL0434两项试验中4925例1-30岁急性淋巴细胞白血病患者的诱导期数据。
主要发现
- 肥胖伴高体表面积者高胆红素血症OR=3.5(95%CI 2.2-5.7)、ALT升高OR=3.3(95%CI 1.7-6.6)、血栓OR=3.1(95%CI 1.5-6.5)。
- 门冬酰胺酶相关毒性与诱导末MRD阳性(≥0.01%)无关联。
关键数值与推荐
- 门冬酰胺酶相关毒性包括高胆红素血症、ALT升高、血栓和胰腺炎。
- 诱导方案包含单剂培门冬酶2500 IU/m2,无最大剂量限制。
- MRD阳性定义为≥0.01%。
临床怎么用
- 对年龄≥10岁及肥胖伴高体表面积的患者应考虑门冬酰胺酶毒性的预防策略。
- 仅高体表面积而无肥胖者不需针对性预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asparaginase-associated toxicities (AAT) often compromise therapy for acute lymphoblastic leukemia (ALL), affecting relapse risk and survival. There are conflicting data on the contributions of older age, obesity by body mass index (BMI), and/or large body surface area (BSA) to AAT. We examined the association of these risk factors with AAT and the impact of AAT on disease response. Induction data were examined from 4925 patients aged between 1 and 30 years enrolled in the Children's Oncology Group ALL trials AALL0232 and AALL0434, which included a single dose of pegaspargase (2500 IU/m2) without a maximum dose. The associations of age, BMI, and BSA with hyperbilirubinemia, elevated alanine aminotransferase (ALT), thrombosis, and pancreatitis were evaluated. The impact of AAT on minimal residual disease (MRD) positivity (≥0.01%) at the end of induction (EOI) was assessed. Increased risk of developing at least 1 AAT was observed in patients aged ≥10 years (P = .002) and in those with obesity and high BSA (P< .0001) but not with high BSA alone. Risks for hyperbilirubinemia, ALT elevations, and thrombosis were all increased in patients with obesity and high BSA (odds ratio [OR], 3.5; 95% confidence interval [CI], 2.2-5.7; OR, 3.3; 95% CI, 1.7-6.6; and OR, 3.1; 95% CI, 1.5-6.5, respectively). AAT were not associated with EOI MRD positivity. To our knowledge, we report the largest data set of AAT in children, adolescents, and young adults. Preventive strategies are indicated for older patients and for those with obesity and high BSA, but not with high BSA alone. These trials were registered at www.clinicaltrials.gov as NCT00075725 and NCT00408005.
引用
- Orgel E, Maese LD, Devidas M, et al. Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group. Blood Adv. 2026. PMID: 42085640. doi:10.1182/bloodadvances.2026019870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。